| Drug resistance and new therapies in colorectal cancer K Van der Jeught, HC Xu, YJ Li, XB Lu, G Ji World journal of gastroenterology 24 (34), 3834, 2018 | 504 | 2018 |
| Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer J Xu, Y Liu, Y Li, H Wang, S Stewart, K Van der Jeught, P Agarwal, ... Nature nanotechnology 14 (4), 388-397, 2019 | 121 | 2019 |
| Dendritic cell targeting mRNA lipopolyplexes combine strong antitumor T-cell immunity with improved inflammatory safety K Van der Jeught, S De Koker, L Bialkowski, C Heirman, P Tjok Joe, ... Acs Nano 12 (10), 9815-9829, 2018 | 113 | 2018 |
| Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells S Van Lint, D Renmans, K Broos, L Goethals, S Maenhout, D Benteyn, ... Cancer immunology research 4 (2), 146-156, 2016 | 113 | 2016 |
| Atractylenolide I enhances responsiveness to immune checkpoint blockade therapy by activating tumor antigen presentation H Xu, K Van der Jeught, Z Zhou, L Zhang, T Yu, Y Sun, Y Li, C Wan, ... The Journal of clinical investigation 131 (10), 2021 | 101 | 2021 |
| Particle-mediated intravenous delivery of antigen mRNA results in strong antigen-specific T-cell responses despite the induction of type I interferon K Broos, K Van der Jeught, J Puttemans, C Goyvaerts, C Heirman, ... Molecular Therapy-Nucleic Acids 5, 2016 | 100 | 2016 |
| Targeting the tumor microenvironment to enhance antitumor immune responses K Van der Jeught, L Bialkowski, L Daszkiewicz, K Broos, C Goyvaerts, ... Oncotarget 6 (3), 1359, 2015 | 95 | 2015 |
| Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity K Van der Jeught, PT Joe, L Bialkowski, C Heirman, L Daszkiewicz, ... Oncotarget 5 (20), 10100, 2014 | 85 | 2014 |
| Theranostic radiolabeled anti-CD20 sdAb for targeted radionuclide therapy of non-Hodgkin lymphoma A Krasniqi, M D'Huyvetter, C Xavier, K Van der Jeught, S Muyldermans, ... Molecular cancer therapeutics 16 (12), 2828-2839, 2017 | 74 | 2017 |
| A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice T Liechtenstein, N Perez-Janices, M Gato, F Caliendo, G Kochan, ... Oncotarget 5 (17), 7843, 2014 | 74 | 2014 |
| MAL2 drives immune evasion in breast cancer by suppressing tumor antigen presentation Y Fang, L Wang, C Wan, Y Sun, K Van der Jeught, Z Zhou, T Dong, ... The Journal of clinical investigation 131 (1), 2021 | 70 | 2021 |
| Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours L Bialkowski, A van Weijnen, K Van der Jeught, D Renmans, ... Scientific reports 6 (1), 22509, 2016 | 68 | 2016 |
| Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer Y Liu, J Xu, HH Choi, C Han, Y Fang, Y Li, K Van der Jeught, H Xu, ... Nature communications 9 (1), 4718, 2018 | 58 | 2018 |
| An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity Z Zhou, K Van der Jeught, Y Fang, T Yu, Y Li, Z Ao, S Liu, L Zhang, ... Nature biomedical engineering 5 (11), 1320-1335, 2021 | 55 | 2021 |
| Heterozygous deletion of chromosome 17p renders prostate cancer vulnerable to inhibition of RNA polymerase II Y Li, Y Liu, H Xu, G Jiang, K Van der Jeught, Y Fang, Z Zhou, L Zhang, ... Nature communications 9 (1), 4394, 2018 | 38 | 2018 |
| Somatic mutation of the cohesin complex subunit confers therapeutic vulnerabilities in cancer Y Liu, H Xu, K Van der Jeught, Y Li, S Liu, L Zhang, Y Fang, X Zhang, ... The Journal of clinical investigation 128 (7), 2951-2965, 2018 | 36 | 2018 |
| Immune checkpoint blockade combined with IL‐6 and TGF‐β inhibition improves the therapeutic outcome of m RNA‐based immunotherapy L Bialkowski, K Van der Jeught, S Bevers, P Tjok Joe, D Renmans, ... International journal of cancer 143 (3), 686-698, 2018 | 35 | 2018 |
| ST2 as checkpoint target for colorectal cancer immunotherapy K Van der Jeught, Y Sun, Y Fang, Z Zhou, H Jiang, T Yu, J Yang, ... JCI insight 5 (9), 2020 | 32 | 2020 |
| Pharmacokinetics of radiolabeled dimeric sdAbs constructs targeting human CD20 A Krasniqi, M Bialkowska, C Xavier, K Van der Jeught, S Muyldermans, ... New biotechnology 45, 69-79, 2018 | 22 | 2018 |
| Targeted immunotherapy for HER2-low breast cancer with 17p loss Y Li, Y Sun, M Kulke, T Hechler, K Van der Jeught, T Dong, B He, ... Science translational medicine 13 (580), eabc6894, 2021 | 20 | 2021 |
Karine BreckpotVrije Universiteit BrusselGeverifieerd e-mailadres voor vub.ac.be
